UPDATED: FDA Approves Quicker-Acting Malignant Hyperthermia Antidote
The FDA has approved Eagle Pharmaceutical Inc's Ryanodex (dantrolene sodium) for the treatment of malignant hyperthermia, along with the appropriate supportive measures.
The FDA has approved Eagle Pharmaceutical Inc's Ryanodex (dantrolene sodium) for the treatment of malignant hyperthermia, along with the appropriate supportive measures.